Athersys receives FDA’s Fast Track designation for MultiStem therapy for acute respiratory distress syndrome

Cleveland biotechnology company Athersys Inc. (Nasdaq: ATHX) announced that its MultiStem cell therapy product has received Fast Track designation from the U.S. Food and Drug Administration in acute respiratory distress syndrome, or ARDS.

The designation comes in the wake of what the company in a news release characterized as “favorable top-line results from a randomized, double-blind placebo-controlled exploratory Phase 2 clinical study” in January evaluating MultiStem administration to patients with ARDS.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published May 17, 2019.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: